Enterprise Sponsor

POLAND

ROAD TO 2021 SPONSOR

Polpharma Biologics

polpharma_img1_658x412@2x

 

About Polpharma Biologics:

Polpharma Biologics, our exclusive sponsor of Poland, is a fast-growing company that develops and manufactures new molecular entities (NMEs) and biosimilars. The company not only creates cell lines and optimizes production processes, but also enables the production of biologics on a commercial scale, both for its own products and to provide contract manufacturing services to industry partners around the world.

Polpharma Biologics has multiple international centers of excellence in Poland and the Netherlands specializing in cell line development, product and process development, clinical manufacturing, commercial scale production, and regulatory affairs.

Polpharma Biologics’ facilities offer state-of-the-art equipment and are staffed with a talented and diverse team of industry veterans with years of experience at big pharma and biotech companies.

VISIT COMPANY WEBSITE

 

polpharma_img2_658x412@2x

 

How is Polpharma Biologics contributing to the future of healthcare?

Polpharma Biologics works with partners to advance their biological pipeline (biosimilars and novel biologics) by providing world-class contract development and manufacturing services to the industry to help partners take their product from concept to commercial supply.

For the development of novel biologics, they also provide proprietary solutions for discovery (CASH™), cell line development (CHOBC®), and process development (SPOT™ and SLIM™) to achieve high yields and high quality and to accelerate products to patients.

For biosimilars, their capabilities are designed to help partners provide patients worldwide with access to the most advanced life-saving and life-improving therapies available. They leverage their large molecule capabilities to develop biosimilars that have no meaningful difference from their reference product in terms of safety and efficacy and are more affordable than the originator drug.

Polpharma Biologics is also expanding its drug substance manufacturing capacity with a large-scale manufacturing plant in Warsaw to increase its ability to assist partners with their clinical and commercial supply.